Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
Annals of Oncology, 06/12/2012
Albiges L et al. – This subdivision is important because it takes into account the nature and severity of clinical symptoms potentially related to non–infectious pneumonitis (NIP), either the onset of new symptoms or the worsening of existing symptoms, and thus determines the type and frequency of follow–up. It also helps to identify a subgroup of patients in whom treatment, if effective, may be continued without dose adjustment.